ACSL4 has been recently proved as a critical ferroptosis promoter in many non-tumor disease models, like organ intestinal/reperfusion [26, 49], ischemic stroke [50], acute kidney injury [51, 52], diabetic retinopathy [53], rhabdomyolysis [54], chronic prostatitis [55], and others. This evidence concerns the gene ACSL4 and neoplasm.